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Background: Bacterial melanin has been proven to stimulate regeneration after CNS lesions. The purpose of this
study was to test, whether bacterial melanin can enter the brain via the blood–brain barrier (BBB).
Methods: Bacterial melanin (BM) was radioactively labeled by the iodobead method and used to test the BBB
permeability after systemic injection into rats. The unidirectional influx rate from the blood was calculated by
multiple-time regression analysis. A subgroup of the animals was co-injected with non-labeled BM to determine if
BM has a saturable transport across the BBB. The levels of radioactivity were determined in the serum and tissues.
Arterial blood was sampled to obtain the level of I-BM at different time points after injection. After systemic perfusion
with saline, animals were decapitated and brain, spinal cord, liver and kidney samples were obtained and homogenized
to test the I-BM level.
Results: Study results showed that radioactively-labeled bacterial melanin crossed the BBB, was enzymatically stable in
blood and in brain parenchyma. Entry to brain was reduced when non-labeled BM was also present. Circulating
melanin entered all regions of the CNS but the uptake was higher in lumbar spinal cord, thalamus, hypothalamus
and substantia nigra. Liver and kidneys had high uptake rates of BM.
Conclusions: These results show that bacterial melanin has saturable transport across the BBB and selectively
targets some CNS regions. Such transport may contribute to the neuroprotective action of bacterial melanin.
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Peptide and protein drugs have shown great potential for
the treatment of various neurodegenerative diseases. A
major challenge in the pharmacokinetics of such drugs is
the delivery of peptides or proteins across the blood–brain
barrier (BBB). Despite the importance of the BBB for neu-
rotherapeutics, the BBB receives insufficient attention in
research. Both, the lack of effort in developing solutions to
the BBB problem, and the minimal BBB transport of the
majority of all potential neuroprotective agents, has led
consequently to the present situation in neurotherapeu-
tics. As a result there are few effective treatments for the
majority of neurodegenerative disorders. This situation
can be changed by an accelerated effort to create a know-
ledge base in the fundamental transport properties of the
BBB, and the molecular and cellular biology of the brain* Correspondence: tipetrosyan@hsc.wvu.edu
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article, unless otherwise stated.capillary endothelium [1]. There are many methods to
quantify the BBB permeability to various test compounds
[2]. Different in vivo approaches include pharmacokinetic
analysis, intracerebral microdialysis, positron emission
tomography, magnetic resonance imaging, and histochem-
istry. In vitro techniques typically use tissue culture
models of cerebrovascular endothelial cells either alone or
co-cultured with astroglia. In vivo techniques to test BBB
permeability include in situ brain perfusion, the intraven-
ous injection/multiple time point approach, and the brain
efflux index procedure. These techniques can be used for
a broad array of substances, ranging from synthesized new
chemical entities to biotechnology-derived peptides and
proteins [3].
For the last decade the efforts of researchers to investi-
gate neurodegenerative disorders have been focused on
the problem of regulating activity in dopaminergic neu-
rons [4]. The goal has been not only to identify theMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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rons, but also the routes for regulation and methods used
to prevent changes in neuronal activity in such patients.
Treatment options for neurodegenerative disorders have
provided clinicians with a number of neuroprotective
agents, each with a different chemical composition and
mechanism of action. Many of the offered options aim to
support cell survival and accelerate posttraumatic recov-
ery of CNS function.
A number of studies have shown the neuroprotective
action of melanocyte-stimulating-hormone on locomotor
recovery following CNS lesions [5-7]. Currently melanins
of various origins are being actively studied and applied as
therapeutic agents. Melanins are multicoloured pigments
of polymer structure. They are unique transmitters of en-
ergy with the property of an amorphous semiconductor.
They can absorb the energy and convert it into various
types of energy [8-10]. Melanins break free radical chain
reactions and accomplish antioxidant protection. These
unique abilities of melanin explain its presence in tissues
and organs connected with impulse transmission, such as
skin, retina, inner ear and nervous system. Disorders of
melanin metabolism may be involved in the etiology of
such diseases as Parkinsonism, senile macular degener-
ation, and senile deafness [11,12]. This pigment is also
relevant to the well-known association between pigment
abnormalities and deafness (Warrensburg’s and Usher’s
syndromes) [13,14]. Furthermore, Alzheimer’s disease and
Down’s syndrome were observed to be also accompanied
with pathological disorders in melanin metabolism [15].
The majority of synthetic and natural melanins are insol-
uble in water. This significantly complicates preparation
of melanin-containing pharmacological and cosmetic
preparations. Obtaining low-cost soluble natural melanin
can essentially stimulate and speed up the use of melanin
in medicine, cosmetology and other fields. For the first
time, a melanin-synthesizing bacterial strain, Bacillus
thuringiensis, with a high level of pigment synthesis was
obtained. The ecologically-safe technology of biosynthesis,
isolation and purification of bacterial melanin (BM) has
been elaborated [16]. Biotechnologically-obtained bac-
terial melanin exhibits a similar infra-red absorption
spectrum to synthetic melanin and contains quinolic
and phenolic substances and around 20% amino acids
after acid hydrolysis. The molecular weight of the puri-
fied melanin determined by SDS-PAGE was 4 kDa and
the electromagnetic spin resonance spectrum of the
purified microbial melanin was a slightly asymmetric
singlet without hyperfine structure with about 7 Gauss
width of the line between points of the maximum incline
and g = 2.006. The concentration of paramagnetic centers
in melanin is 0.21 · 1018 spin/g. BM is homogenous in
polymeric structure and does not contain polymers of
tyrosine of different length [16].The biological activity of melanin has been studied on
both animals and plants [17-19]. In experiments on la-
boratory animals (Wistar rats) with brain surgical
trauma, it was revealed that BM facilitated the recovery
of instrumental conditioned reflexes after unilateral abla-
tion of sensorimotor cortex that had caused paresis of
limbs [20]. In addition, low doses of BM accelerated the
recovery of physiological functions lost because of ner-
vous tissue damage [21]. In a previous experimental
series, we have shown the neuroprotective action of BM
after neurotrauma in the CNS in that BM accelerates
motor recovery and enhances regeneration after sub-
stantia nigra lesions [22]. Injection of BM increases elec-
trical activity of substantia nigra dopaminergic neurons
[23], although it remained unclear whether the BM is
able to cross the BBB or not. The goal of the present
study was to test the ability of BM to cross the BBB
using the method of radioactive labelling.
Methods
Animals
Experimentally-naïve male Wistar rats (n = 12) were
used at 3–6 months of age and weighed 180–200 g at
the start of experiment. Rats were housed with their lit-
termates in plastic boxes covered by a wire lid and were
maintained on a standard light–dark cycle with food and
water available ad libitum. Animals were maintained
and handled in accordance with institutional guidelines
and national and international laws and policies (EEC
Council Directive 86/609, OJ L 358, 1, December 12,
1987; NIH Guide for the Care and Use of Laboratory
Animals, NIH Publication No. 86–23, 1985). All efforts
were made to minimize the number of animals used in
this study and their suffering.
Radioactive labeling of bacterial melanin
BM was radioactively labeled by the iodobead method
[24]. Briefly, 100 μl of 0.1% SB3-14 (sulphobetaine) in
0.25 M sodium phosphate buffer solution and 2 mCi 131I
were collected into a tube to prevent the aggregation.
The iodiobead added mixture was incubated for 5 min
at room temperature. BM (10 μg) was added and the
mixture was incubated for 5 min and then added to a
previously-washed gel filtration medium (G-10 Sepha-
dex) column and eluted with 0.1% SB3-14 in 0.25 M so-
dium phosphate buffer, pH 7.4. I-BM eluted in fraction 8
(retention factor - RF was 1.8%) with 85% precipitation
in acidified brine (30% trichloroacetic acid in a saturated
solution of NaCl).
Measurements of I-BM uptake
Rats were anesthetized with 40% urethane (intraperito-
neal, 1.2 g / kg). The right jugular vein and the left ca-
rotid artery were exposed and 0.4 ml of lactated Ringer’s
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and 250,000 cpm I-BM was injected into the jugular
vein. Six of the animals were also injected with 50 μg/rat
of unlabeled BM, to determine the nature of melanin
uptake. At various time points (5, 20, 30, 45 and 60 min)
after the iv injection, blood was obtained from the ca-
rotid artery. In rats injected with cold BM arterial blood
was sampled every 1 minute. The arterial blood was cen-
trifuged to collect arterial serum. The levels of radio-
activity were determined for the serum, brain, liver and
kidney tissues in a gamma counter. Results were expressed
as tissue/serum ratios (μl/g) of I-BM. After the last sample
was obtained, the animals were perfused systemically and
then decapitated (see below).
The unidirectional influx rate (Ki, in units of μl/g-min)
into brain was derived by multiple-time regression ana-




where Abr is the amount in the extravascular compart-
ments of brain per unit mass of brain tissue at time t,
Ĉp is the amount of radioactivity in serum at time t. The
brain/serum ratio was plotted against exposure time






[26] where Cp(T) is the concentration in arterial serum,
and T is the dummy variable for time, dT is the appar-
ent diffusion constant through brain tissue at 37°C.Figure 1 Graph of influx of bacterial melanin into brain (Abr/(Ĉp · t)) a
linear fit of all the data points. The slope of the line is equivalent to KI (rate
ordinate intercept is equivalent to VI (functional distribution volume of theWhen a test substance moves unidirectionally from








where KI is the rate of unidirectional solute flux from
plasma across the barrier into the brain divided by the
plasma concentration, and VI is the functional distribution
volume of the substance that exchanges with plasma.
Arterial serum obtained at different time points after
the iv injection of I-MB was allowed to clot and 50 μl of
the resulting serum added to 250 μl of LR-BSA and then
to 250 μl of acidified brine containing 30% trichloroacetic
acid. The mixture was stirred and centrifuged at 5600 × g
for 15 min at 4°C. The supernatant and precipitate were
separated and counted. The results were expressed as the
percent of total precipitated amount.
Brain perfusion procedure
Brain perfusion with saline was performed to remove
the blood from the brain microvessels before decapita-
tion because the radioactivity in brain microvessels
could be a confounding factor in the correct interpret-
ation of the data from brain parenchyma.
Under urethane anesthesia, a 1–1.5 cm-long incision
was made with the scissors midway between the trachea
and esophagus and the shoulder of the rat. Subcutane-
ous fat and muscle tissues were removed using curved
microdissecting forceps to expose the right carotis com-
munis artery (CCA) and the bifurcation of the right ex-
ternal and internal carotid artery (ECA and ICA). The
ECA was ligated with a 4.0 suture rostrally (towards thegainst exposure time ([∫Cp(T)dT]/cpt). The solid line represents the
of unidirectional solute flux from plasma across the BBB) and the
substance that exchanges with plasma).
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ECA and ICA. Loose ligature was placed around the
CCA caudally (towards the tail) before the bifurcation of
the right ECA and ICA. Small arterial branches of ICA
and ECA were cauterized using electrocautery. The
PE50 polyethylene perfusion cannula was filled with
Krebs-bicarbonate buffer and connected to a 20 ml
syringe using a cut 22-G needle. The syringe containing
the saline solution was placed in the infusion pump. The
CCA was catheterized caudally (before the bifurcation)
with the buffer-filled perfusion cannula (with the tip of
the cannula pointing towards the head) and fixed using
a 4.0 suture. The chest cavity of rat was opened quickly
and the cardiac ventricles severed. The pump was
turned on to start the perfusion. The brain was perfused
for 3 min at a rate of 5 ml/min. An aliquot (0.25 ml) of
the perfusate was obtained for test compound concentra-
tion analysis (Figure 2). The procedure was performed in
the shortest possible time period to prevent cerebral ische-
mia. After the perfusion, rats were quickly decapitated.
Tissue preparation
The whole brain, spinal cord, liver and kidney were ob-
tained from each rat after decapitation. The brains were
dissected into 10 regions (frontal cortex, parietal cortex,
occipital cortex, substantia nigra, hippocampus, hypo-
thalamus, thalamus, pons medulla, cerebellum, and mid-
brain) according to the method of Glowinski & Iversen
[27] and the spinal cord divided into 3 regions: cervical,
thoracic, and lumbar. In their study, Glowinski &
Iversen also isolated the striatum but we have included
the substantia nigra as this region is the target of our re-
search project. The substantia nigra was dissected bilat-
erally by a special razor. The cuts were made caudal to
the mammillary bodies, rostral to the pons, lateral to the
interpeduncular nucleus, and along a line extendingFigure 2 Precipitation of radioactivity in serum. Results are shown as th
The green line indicates percent of radioactivity in the perfusate. Figure shthrough the medial lemniscus to the lateral edge of the
brain stem. The sample included substantia nigra pars
compacta and pars reticulata. Brain and spinal cord sam-
ples were weighed, the level of radioactivity measured as
described below, and the results expressed as the brain/
serum ratios in μl/g.
The samples were homogenized with a glass homogenizer
in 3 ml of LR-BSA and then centrifuged at 5600 × g for
10 min at 4°C. An aliquot of 1.5 ml of the supernatant
was added to 1.5 ml of acidified brine containing 30%
trichloroacetic acid. The mixture was stirred and then
centrifuged at 5600 × g for 10 min at 4°C. The super-
natant and precipitate were separated and counted. The
results were expressed as the percentage of total precip-
itated counts. The same procedure was used for the
liver and kidney samples.
To estimate degradation rate during the process of
acid precipitation, I-BM was added to non-radioactive
arterial whole blood and to whole brain. These samples
were then processed according to the above described
procedure and the percentage of total precipitated
counts was determined. The mean value obtained from
controls was 78% for serum and 67% for brain. The
values for the experimental samples were divided by the
value obtained from control and multiplied by 100 to get
the final results.
Statistical processing
Mean values of measurements are presented with their
standard deviations. Mean values were compared using
t-test. One-way ANOVA was used to compare regional
uptake rates to whole brain.
Results and discussion
In Table 1 the results for brain and serum are compared.
The degradation rate of I-BM was significantly lower ine percent of control radioactivity that precipitated with acidified brine.
ows that the radioactivity in serum declined over time.
Table 1 Precipitation of radioactivity from brain and
serum.
5 min 20 min 30 min 45 min 60 min
Brain
(% of control)
122 ± 3.6 118 ± 1.8 112 ± 1.6 107 ± 1.4 104 ± 0.90
Serum
(% of control)
114 ± 2.4 111 ± 3.9 106 ± 4.4 98 ± 3.2 92 ± 3.4
Results are shown as the percent of control radioactivity that precipitates with
acidified brine. Means ± SD, for the group (n = 6).
Table 3 Uptake of bacterial melanin by CNS and CNS
regions after intravenous bolus injection
CNS region Tissue/serum ratio (μl/g)
Frontal cortex 29.5 ± 1.9
Parietal cortex 22.2 ± 2.7
Occipital cortex 21.8 ± 1.8
Hypothalamus 36.6 ± 6.3
Thalamus 44.8 ± 8.4
Substantia nigra 60.7 ± 10.2
Hippocampus 28.2 ± 3.1
Cerebellum 32.1 ± 3.2
Midbrain 29.4 ± 2.8
Pons medulla 26.5 ± 1.8
Cervical spinal cord 33.3 ± 2.9
Thoracic spinal cord 28.2 ± 2.8
Lumbar spinal cord 58.2 ± 7.3
Whole CNS 26,7 ± 2.8
Results are expressed as tissue/serum ratios (μl/g). Means ± SD for the
group (n = 6).
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seen at 30 min but with a significant level of non-
degraded I-BM still in serum at 60 min. The curve in
Figure 1 shows the uptake of I-BM by brain in rats co-
injected with non-labeled bacterial melanin. Brain up-
take was almost linear for 20 min of exposure after i/v
injection with a Ki of approximately 1.0 ul/g-min. How-
ever, there was a statistically significant decrease in the
Ki for brain after 40 minutes of exposure: 0.218 ± 0.08
(p < 0.05, Table 2). This shows that transport of BM
across the BBB involves a saturable transport system and
the influx of BM into the CNS prevails over the efflux.
Table 3 shows the uptake of BM into brain and spinal cord
regions. Statistical comparison of the whole brain value to
brain regions showed a significant variation (p < 0.01). The
hypothalamus, thalamus, substantia nigra and lumbar re-
gion of the spinal cord showed higher uptake in compari-
son to whole brain. The highest uptake rate was in the
thalamus and substantia nigra. In rats injected with mix-
ture of I-BM and 50 μg/rat of cold BM, inhibition of up-
take was revealed for the whole brain. Table 2 shows that
inclusion of unlabeled BM significantly inhibited the efflux
of I-BM. The values for whole brain were estimated by
adding together the levels of radioactivity and weights for
all the brain regions. To evaluate the elimination routes of
I-BM, brain, liver and tissue samples were obtained. The
rates of I-BM uptake by different tissues are presented in
Table 2. The highest rate was registered for the substantia
nigra. The uptake rate was significantly higher also in lum-
bar spinal cord and thalamus.
The purpose of the study was to test the ability of BM
to cross the BBB. BM has been studied in various
models of neurodegeneration and the results suggest
that it reaches the brain parenchyma, as it induces signifi-
cant regeneration in CNS after trauma and acceleratesTable 2 Rates of radioactive bacterial melanin uptake by
brain, liver and kidneys after intravenous bolus injection
Brain Liver Kidney
Uptake rate of I-BM 0.218 ± 0.07 9.7 ± 2.4 17.4 ± 3.3
Uptake rate of I-BM mixed with
50 μg/rat of cold BM
0.084 ± 0.008* 4.4 ± 1.2 18.2 ± 4.1
Data are expressed as μl/g-min 40 minutes after injection. Means ± SD for the
group (n = 6), *P < 0.05.motor recovery [22]. In a previous series, studying effects
of BM on regeneration and motor recovery after destruc-
tion of sensorimotor cortex, we have tested the availability
of BM in the brain tissue by HPLC (Petrosyan TR, unpub-
lished data), although we did not study the kinetics of BM
in the whole organism. HPLC confirmed the presence of
structurally-intact BM in the brain tissue after injection.
In the present work we focused mostly on the pharmaco-
kinetic aspects to obtain evidence for the ability of mel-
anin to cross the BBB. This confirmed the ability of BM to
cross BBB and reach brain tissue. Co-injection of excess
amount of unlabeled BM showed that transport of radio-
actively labeled I-BM across the BBB is saturable. Entry of
BM into the brain was linear for the first 20 exposure
minutes and the influx itself was saturable, meaning that
transport of BM through BBB was basically unidirectional.
The influx rate in BM co-administered rats started to de-
crease after 20 minutes. BM showed enzymatic stability in
both blood and brain tissue. This suggests that blood-
introduced BM could contribute significantly to brain
levels of BM. Labeled BM had a significant residence time
in blood, so any amount of BM introduced into the
bloodstream has a significant period to cross the BBB.
Moreover, brain residence time appeared to be longer
than the blood residence time. Therefore BM has a fa-
vorable pharmacokinetic profile for use as a therapy for
neuroprotection. BM uptake rate differed widely
throughout the CNS and the thalamus and substantia
nigra had higher uptake rates than other regions. Re-
search interest was focused on the substantia nigra as it
is affected by neurodegeneration. The lumbar spinal
cord showed the second highest uptake rate of any
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The uptake of BM by a number of brain regions raises
the possibility that it may be affecting various aspects
of brain function or even altering BBB function.
Despite the fact that BM can cross the BBB, it is not
known whether BM uses a melanin transporter to do so.
There is not much data on the transport of melanin and
its mediators. However, Berliner et al. mentioned the
possible role of melanin as a transporter that crosses the
BBB and has a potential for pharmacological application
as a transporter [28]. For example, melanin easily binds
to nerve growth factor, and transports it across the
blood–brain barrier. By transporting nerve growth factor
across the blood–brain barrier and increasing the per-
meability of the blood–brain barrier, melanin is useful in
allowing nerve growth factor to reach the brain tissue
[29]. To add more information to the pharmacokinetic
profile of the BM we also tested the uptake rate of I-BM
into liver and kidneys. Results showed that uptake rate
was almost two-fold higher in kidneys, meaning that
bacterial melanin accumulates in the kidneys and less so
in the liver.
Conclusions
In summary, BM is enzymatically stable in blood and in
brain parenchyma and is transported by a saturable mech-
anism into the CNS parenchyma. Uptake from blood oc-
curs throughout the CNS and is particularly high for the
substantia nigra, hypothalamus, thalamus and lumbar
spinal cord. Radioactively labeled BM is more stable in
brain, suggesting that BM introduced into the blood or
peripheral tissue (intramuscular injection) could contrib-
ute to the levels of melanin in CNS parenchyma.
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